登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Lancet，7月6日，Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-07-15

  • Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

    Prof Marina Pollán, MD

    Beatriz Pérez-Gómez, MD

    Roberto Pastor-Barriuso, PhD

    Jesús Oteo, PhD

    Miguel A Hernán, MD

    Mayte Pérez-Olmeda, PhD

    et al.

    Show all authors

    Show footnotes

    Published:July 06, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31483-5

    Summary

    Background

    Spain is one of the European countries most affected by the COVID-19 pandemic. Serological surveys are a valuable tool to assess the extent of the epidemic, given the existence of asymptomatic cases and little access to diagnostic tests. This nationwide population-based study aims to estimate the seroprevalence of SARS-CoV-2 infection in Spain at national and regional level.

    Methods

    35?883 households were selected from municipal rolls using two-stage random sampling stratified by province and municipality size, with all residents invited to participate. From April 27 to May 11, 2020, 61?075 participants (75·1% of all contacted individuals within selected households) answered a questionnaire on history of symptoms compatible with COVID-19 and risk factors, received a point-of-care antibody test, and, if agreed, donated a blood sample for additional testing with a chemiluminescent microparticle immunoassay. Prevalences of IgG antibodies were adjusted using sampling weights and post-stratification to allow for differences in non-response rates based on age group, sex, and census-tract income. Using results for both tests, we calculated a seroprevalence range maximising either specificity (positive for both tests) or sensitivity (positive for either test).

  • 原文来源：https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31483-5/fulltext#%20
27浏览量
原文链接
相关报告

  • 《Lancet，6月11日，Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-12
    • Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study Silvia Stringhini, PhD Ania Wisniak, MS † Giovanni Piumatti, PhD † Andrew S Azman, PhD † Stephen A Lauer, PhD Hélène Baysson, PhD et al. Published:June 11, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31304-0 Summary Background Assessing the burden of COVID-19 on the basis of medically attended case numbers is suboptimal given its reliance on testing strategy, changing case definitions, and disease presentation. Population-based serosurveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies provide one method for estimating infection rates and monitoring the progression of the epidemic. Here, we estimate weekly seroprevalence of anti-SARS-CoV-2 antibodies in the population of Geneva, Switzerland, during the epidemic. Methods The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. We planned a series of 12 consecutive weekly serosurveys among randomly selected participants from a previous population-representative survey, and their household members aged 5 years and older. We tested each participant for anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA. We estimated seroprevalence using a Bayesian logistic regression model taking into account test performance and adjusting for the age and sex of Geneva's population. Here we present results from the first 5 weeks of the study.
    17浏览量
    原文链接

  • 《bioRxiv，6月7日，Rapid inactivation of SARS-CoV-2 with Deep-UV LED irradiation》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-09
    • Rapid inactivation of SARS-CoV-2 with Deep-UV LED irradiation Hiroko Inagaki, akatsuki Saito, Hironobu Sugiyama, Tamaki Okabayashi, Shouichi Fujimoto doi: https://doi.org/10.1101/2020.06.06.138149 Abstract The spread of novel coronavirus disease 2019 (COVID-19) infections worldwide has raised concerns about the prevention and control of SARS-CoV-2. Devices that rapidly inactivate viruses can reduce the chance of infection through aerosols and contact transmission. This in vitro study demonstrated that irradiation with a deep ultraviolet light-emitting diode (DUV-LED) of 280 ± 5 nm wavelength rapidly inactivates SARS-CoV-2 obtained from a COVID-19 patient. Development of devices equipped with DUV-LED is expected to prevent virus invasion through the air and after touching contaminated objects. Competing Interest Statement The authors have declared no competing interest.
    113浏览量
    原文链接